Program
Panitumumab
Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 351 open or running | phase 3since Jun 10, 2005 | Apr 25, 2002 | Sep 25, 2028phase 3 · NCT06252649 |
| Dr. Reddy's Laboratories | 10 open or running | phase 4since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| R-Pharm | 11 open or running | phase 1since Apr 14, 2026 | Apr 14, 2026 | none ahead |
Also a collaborator on its studies: Takeda and immunex-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Apr 25, 2002.
- Mar 8, 20072 phase 2 studiesAmgen · NCT00446446, NCT00454779
- Jul 12, 20072 phase 2 studiesAmgen · NCT00500760, NCT00508404
- Oct 18, 2007Phase 2 study in NeoplasmsAmgen · NCT00547157 · 152 enrolled
- Nov 21, 2007Phase 1 study in Colorectal NeoplasmsAmgen · NCT00563316 · 28 enrolled · United States, Canada
- Jan 31, 2008Phase 2 study in Pancreatic NeoplasmsAmgen · NCT00613730 · 3 enrolled
- Apr 10, 2008Phase 1 study in Solid TumorsAmgen · NCT00658658 · 31 enrolled · United States
- Sep 18, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckAmgen · NCT00756444 · 67 enrolled
- Nov 6, 2008Phase 2 study in Colonic NeoplasmsAmgen · NCT00819780 · 285 enrolled · United States, Belgium, Canada and more
- Oct 22, 2009Phase 3 study in Colorectal NeoplasmsAmgen · NCT01001377 · 1,010 enrolled · United States, Australia, Belgium and more
- Mar 31, 2011Phase 3 study in Colorectal NeoplasmsAmgen · NCT01412957 · 377 enrolled · Brazil, Canada, Chile and more
- Nov 24, 2014Dr. Reddy's Laboratories's first study: phase 4 study in NeoplasmsNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02301962 · 58 enrolled · India
- Jan 6, 2022Phase 3 study in Colorectal NeoplasmsAmgen · NCT05198934 · 160 enrolled · United States, Australia, France and more
- Jan 15, 2024Phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649 · 450 planned · United States, Argentina, Australia and more
- Apr 14, 2026R-Pharm's first study: phase 1 study in Colorectal NeoplasmsNew to R-PharmR-Pharm · NCT07543744 · 180 planned · Russia
Ahead
- Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649
TargetBeta
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07543744Colorectal Neoplasms · Russia | 1 | Recruiting | R-Pharm | May 15, 2026 | 180 |
| NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Amgen | Sep 25, 2028 | 450 |
| NCT05198934Colorectal Neoplasms · United States, Australia, France and more | 3 | Completed | Amgen | Jul 16, 2025 | 160 |
| NCT02301962Neoplasms · India | 4 | UNKNOWN | Dr. Reddy's Laboratories | Jun 30, 2021 | 58 |
| NCT01412957Colorectal Neoplasms · Brazil, Canada, Chile and more | 3 | Completed | Amgen | Jun 2014 | 377 |
| NCT01001377Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Amgen | Feb 5, 2013 | 1,010 |
| NCT00819780Colonic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Amgen | May 30, 2012 | 285 |
| NCT00756444Squamous Cell Carcinoma of Head and Neck | 2 | Completed | Amgen | Mar 30, 2012 | 67 |
| NCT00658658Solid Tumors · United States | 1 | Completed | Amgen | Mar 2015 | 31 |
| NCT00613730Pancreatic Neoplasms | 2 | Terminated | Amgen | Apr 2009 | 3 |
| NCT00563316Colorectal Neoplasms · United States, Canada | 1 | Completed | Amgen | Mar 2009 | 28 |
| NCT00547157Neoplasms | 2 | Completed | Amgen | Dec 2011 | 152 |
| NCT00508404Colorectal Neoplasms | 2 | Completed | Amgen | Jun 1, 2009 | 154 |
| NCT00500760Head and Neck Neoplasms | 2 | Completed | Amgen | Mar 29, 2011 | 153 |
| NCT00454779Neoplasm Metastasis · United States, Austria, Belgium and more | 2 | Completed | Amgen | Jun 11, 2012 | 113 |
| NCT00446446Neoplasms | 2 | Completed | Amgen | Dec 15, 2010 | 52 |
| NCT00425204Colorectal Neoplasms | 2 | Completed | Amgen | Sep 2007 | 31 |
| NCT00425035Kidney Neoplasms | 2 | Completed | Amgen | 115 | |
| NCT00418938Neoplasms | 2 | Completed | Amgen | May 10, 2012 | 266 |
| NCT00411450Colonic Neoplasms | 2 | Completed | Amgen | Jan 2009 | 116 |
| NCT00364013Colorectal Neoplasms | 3 | Completed | Amgen | Aug 1, 2009 | 1,183 |
| NCT00339183Colorectal Neoplasms | 3 | Completed | Amgen | Apr 1, 2009 | 1,186 |
| NCT00327119Colorectal Neoplasms | 2 | Completed | Amgen | 50 | |
| NCT00352950Neoplasms | 1 | Withdrawn | Amgen | 0 | |
| NCT00115765Colorectal Neoplasms | 3 | Completed | Amgen | May 31, 2007 | 1,053 |
| NCT00113776Colorectal Neoplasms | 2 | Completed | Amgen | ||
| NCT00113763Colorectal Neoplasms | 3 | Completed | Amgen | Oct 1, 2008 | 463 |
| NCT00111774Colorectal Neoplasms | 2 | Completed | Amgen | 150 | |
| NCT00111761Colorectal Neoplasms | 2 | Completed | Amgen | Feb 2008 | 43 |
| NCT00101920Carcinoma, Non-Small-Cell Lung | 2 | Completed | Amgen | Dec 2004 | 50 |
| NCT00101907Lung Neoplasms | 1 | Terminated | Amgen | Jun 2007 | 41 |
| NCT00094835Lung Neoplasms | 2 | Completed | Amgen | Mar 2007 | 51 |
| NCT00091806Neoplasms | 1 | Completed | Amgen | Apr 2006 | 86 |
| NCT00089635Colorectal Neoplasms | 2 | Completed | Amgen | Jan 1, 2007 | 203 |
| NCT00083616Colorectal Neoplasms | 2 | Completed | Amgen | May 2007 | 185 |
| NCT00061126Prostatic Neoplasms · United States | 2 | Completed | Amgen | 50 | |
| NCT00034346Carcinoma, Non-Small-Cell Lung | 2 | Completed | Amgen | 194 |
How it is read
Names in the registry
- “Panitumumab”, 29 entries
- “ABX-EGF”, 5 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “Panitumumab (ABX-EGF)”, 2 entries
- “RPH-030”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 25 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colonic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.